Thompson Peter A.

CIK 000135752217 companiesWALTHAM, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001357522

Recent Transactions

50 trades

Sale
Sionna Therapeutics, Inc.$SION
Common Stock
2026-02-03$44.58/sh−29,063→ 3,530,702 total
Sale
Sionna Therapeutics, Inc.$SION
Common Stock
2026-02-02$44.57/sh−1,890→ 3,559,765 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Stock Option (Right to Buy)
2026-01-28−15,000→ 0 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Stock Option (Right to Buy)
2026-01-28−15,000→ 0 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2026-01-28$2.74/sh+15,000→ 120,000 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Stock Option (Right to Buy)
2026-01-28−15,000→ 0 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Stock Option (Right to Buy)
2026-01-28−15,000→ 0 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Stock Option (Right to Buy)
2026-01-28−15,000→ 0 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2026-01-28$9.70/sh+15,000→ 45,000 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2026-01-28$2.49/sh+15,000→ 180,000 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2026-01-28$0.96/sh+15,000→ 165,000 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2026-01-28$15.00/sh+30,000→ 30,000 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2026-01-28$2.12/sh+15,000→ 210,000 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2026-01-28$3.27/sh+15,000→ 105,000 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Stock Option (Right to Buy)
2026-01-28−15,000→ 0 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Stock Option (Right to Buy)
2026-01-28−15,000→ 0 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Stock Option (Right to Buy)
2026-01-28−15,000→ 0 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Stock Option (Right to Buy)
2026-01-28−15,000→ 0 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2026-01-28$12.50/sh+15,000→ 60,000 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2026-01-28$1.64/sh+15,000→ 195,000 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2026-01-28$3.61/sh+15,000→ 75,000 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2026-01-28$2.60/sh+15,000→ 135,000 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Stock Option (Right to Buy)
2026-01-28−30,000→ 0 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Stock Option (Right to Buy)
2026-01-28−15,000→ 0 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2026-01-28$2.00/sh+15,000→ 90,000 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Stock Option (Right to Buy)
2026-01-28−15,000→ 0 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2026-01-28$0.99/sh+15,000→ 150,000 total
Exercise/Conversion
Corvus Pharmaceuticals, Inc.$CRVS
Stock Option (Right to Buy)
2026-01-28−15,000→ 0 total
Sale
Sionna Therapeutics, Inc.$SION
Common Stock
2025-12-19$44.49/sh−875→ 3,595,011 total
Sale
Sionna Therapeutics, Inc.$SION
Common Stock
2025-12-18$44.49/sh−100→ 3,595,886 total
Sale
Sionna Therapeutics, Inc.$SION
Common Stock
2025-12-17$44.50/sh−900→ 3,595,986 total
Sale
Sionna Therapeutics, Inc.$SION
Common Stock
2025-11-26$44.49/sh−1,600→ 3,596,886 total
Sale
Sionna Therapeutics, Inc.$SION
Common Stock
2025-11-25$44.60/sh−11,890→ 3,598,486 total
Sale
Sionna Therapeutics, Inc.$SION
Common Stock
2025-11-24$44.54/sh−94,583→ 3,610,376 total
Sale
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2025-06-27$4.16/sh−1,176,332→ 7,165,006 total
Exercise of In-Money
Corvus Pharmaceuticals, Inc.$CRVS
Common Warrants (right to buy)
2025-06-27−1,397,684→ 0 total
Exercise of In-Money
Corvus Pharmaceuticals, Inc.$CRVS
Common Stock
2025-06-27$3.50/sh+1,397,684→ 8,341,338 total
Award
ARS Pharmaceuticals, Inc.$SPRY
Stock Option (right to buy)
2025-06-25+30,000→ 30,000 total
Award
Edgewise Therapeutics, Inc.$EWTX
Stock Option (Right to Buy)
2025-06-16+30,000→ 30,000 total
Award
Sionna Therapeutics, Inc.$SION
Non-Qualified Stock Option (right to buy)
2025-06-12+19,959→ 19,959 total
Award
Corvus Pharmaceuticals, Inc.$CRVS
Stock Option (Right to Buy)
2025-06-12+15,000→ 15,000 total
Purchase
Edgewise Therapeutics, Inc.$EWTX
Common Stock
2025-04-03$20.13/sh+124,193→ 443,792 total
Purchase
Edgewise Therapeutics, Inc.$EWTX
Common Stock
2025-04-03$20.13/sh+372,578→ 14,809,075 total
Conversion
Sionna Therapeutics, Inc.$SION
Series C convertible preferred stock
2025-02-10−2,048,760→ 0 total
Conversion
Sionna Therapeutics, Inc.$SION
Common Stock
2025-02-10+3,154,959→ 3,154,959 total
Purchase
Sionna Therapeutics, Inc.$SION
Common Stock
2025-02-10$18.00/sh+550,000→ 3,704,959 total
Conversion
Sionna Therapeutics, Inc.$SION
Series B convertible preferred stock
2025-02-10−2,560,951→ 0 total
Sale
ARS Pharmaceuticals, Inc.$SPRY
Common Stock
2024-08-26$13.00/sh−83,695→ 0 total
Sale
ARS Pharmaceuticals, Inc.$SPRY
Common Stock
2024-08-23$13.03/sh−69,500→ 83,695 total
Sale
ARS Pharmaceuticals, Inc.$SPRY
Common Stock
2024-08-22$12.94/sh−391,482→ 153,195 total

Companies

Recent Filings

Address

C/O SIONNA THERAPEUTICS, INC. 21 HICKORY DRIVE SUITE 500

WALTHAM, MA, 02451

View on SEC.gov